Interim results from a retrospective multicenter European study presented serial amino acid PET readouts for vorasidenib (Voranigo) in IDH-mutant glioma. PET Response Assessment in Neuro-Oncology (RANO) 1.0 detected earlier partial responses than structural MRI-based RANO 2.0, with partial responses of 29% versus 6% under the different criteria. The analysis also highlighted metabolic tumor volume change as the key discriminator driving early PET-based response classification. Median time to response was 4 months on PET RANO 1.0 versus 8 months using MRI, aligning with the clinical challenge that imaging tumor volume changes slowly under treatment.
Get the Daily Brief